Literature DB >> 2419524

Prognostic factors for favorable outcome in disseminated germ cell tumors.

R Birch, S Williams, A Cone, L Einhorn, P Roark, S Turner, F A Greco.   

Abstract

Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419524     DOI: 10.1200/JCO.1986.4.3.400

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

3.  Lactate dehydrogenase should be used as marker in testicular tumours.

Authors:  O Hughes; M Bishop
Journal:  BMJ       Date:  1996-09-07

Review 4.  [An interdisciplinary consensus conference on the diagnosis and therapy of testicular tumors].

Authors:  M Bamberg; H J Schmoll; L Weissbach; J Beyer; C Bokemeyer; A Harstrick; W Höltl; R Souchon; H Vogler
Journal:  Strahlenther Onkol       Date:  1997-08       Impact factor: 3.621

5.  Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.

Authors:  A Harstrick; H J Schmoll; C Bokemeyer; B Metzner; H J Illiger; W Berdel; H Ostermann; C Manegold; U Räth; W Siegert
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 6.  Treatment intensification in disseminated germ-cell tumors.

Authors:  J Beyer; C Bokemeyer; H J Schmoll; W Siegert
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.

Authors:  A Moran-Ribon; J P Droz; J Kattan; B Leclercq; M Ghosn; D Couanet; M Ostronoff; S Culine; B Misset; B Escudier
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

Review 8.  Good-risk-advanced germ cell tumors: historical perspective and current standards of care.

Authors:  Darren R Feldman; Robert J Motzer
Journal:  World J Urol       Date:  2009-06-10       Impact factor: 4.226

9.  Application of the International Germ Cell Consensus Classification to the Nova Scotia population of patients with germ cell tumours.

Authors:  Elana Maydanski Murphy; Jo-Anne Douglas; Kara Thompson; Lori Wood
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

Review 10.  High-dose therapy with stem cell support in solid tumors.

Authors:  G Spitzer; F R Dunphy; C E Bowers; D R Adkins
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.